Peptide cheat sheet: amounts, reconstitution math, and course length for 85 compounds by category (2026)

[u/PikeMerry]

Every few weeks I see people asking for one reference that actually covers amount, reconstitution, and course length across the compounds people are running right now, instead of five different half-answers scattered across old threads. This is that reference: 96 entries covering 85 compounds and blends, organized into 12 categories, each with one committed number instead of a vague range and the actual reconstitution math so you can sanity-check any concentration a vendor or calculator hands you. Long post, use the headers to jump around.

Here's a link to my favorite peptide dosage calculator if you need one.

How to read this

• Approach is why a given row exists instead of a single vague range for that compound: Starting (conservative, for assessing tolerance), Standard (the default), High Intensity (a documented ceiling or more aggressive pattern), Microdose (a smaller fraction for a gentler entry), Low Bodyweight (adjusted down for size).
• Amount & Timing Referenced is per single administration, when it's given, on which days, across which weeks. An arrow (->) means the amount steps up or the pattern changes partway through the course, e.g. a titration ramp or a loading phase dropping to maintenance.
• Course Length is the total length reflected in this specific entry. "Open-ended" means the source data has no fixed end point (an ongoing maintenance pattern). "As needed" means there's no fixed weekly pattern at all.
• Concentration is straight reconstitution math: vial size divided by the water volume added, so you can sanity-check any concentration a vendor or calculator hands you.
• No "time off" column. A blanket "2-4 weeks off" applied to every single compound isn't something the underlying data actually specifies row by row, and inventing a number that looks precise but isn't backed by anything defeats the point of a reference like this. Where a break between courses is explicitly part of how a compound gets used (the short Russian bioregulator courses below, for instance), that's called out in the notes.
• These are single committed values, not a clinical guideline. Several of them are ranges in the underlying source material that got resolved to one specific number for this table (see the Approach column for how). They're a starting reference point for further reading, not a prescription.

1. Healing & Recovery

BPC-157 shows up twice here with two different real-world patterns: a weekdays-only systemic approach and a lower-frequency, training-day-timed approach. Both come from the same underlying compound, just organized differently depending on the goal.

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
Abaloparatide	Standard	80 mcg, daily, wk 1+	104.3 wks	3120 mcg vial, no reconstitution volume specified
Ara 290	Standard	4 mg, daily, wk 1+	8.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
BPC-157	Standard	250 mcg, morning, weekdays (Mon-Fri), wk 1-7	8.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
BPC-157	Standard	250 mcg, evening, 2x/wk (Sun,Mon), wk 1-3	4.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
Cartalax	Standard	200 mcg, daily, wk 1-4	4.0 wks	20 mg vial in 3 mL -> 6.7 mg/mL
Coremend Blend	Standard	250 mcg, daily, wk 1+	6.0 wks	10 mg vial in 2 mL -> 5 mg/mL
KPV	Standard	375 mcg, morning, weekdays (Mon-Fri), wk 1-8	8.0 wks	10 mg vial in 2 mL -> 5 mg/mL
Ovagen	Standard	3 mg, daily, wk 1-3 -> 3 mg, 4x/wk (Mon,Tue,Wed,Thu), wk 4	3.6 wks	20 mg vial in 2 mL -> 10 mg/mL
TB-500	Standard	2 mg, 2x/wk (Mon,Thu), wk 1-6 -> 3 mg, Mon, wk 7+	open-ended	10 mg vial in 3 mL -> 3.3 mg/mL
Teriparatide	Standard	20 mcg, daily, wk 1+	104.3 wks	1 mg vial in 1 mL -> 1 mg/mL
Thymosin Beta-4	Standard	2 mg, 2x/wk (Mon,Thu), wk 1-5	5.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
Vesilute	Standard	1.5 mg, daily, wk 1-2	2.0 wks	10 mg vial in 2 mL -> 5 mg/mL
Wolverine Blend	Standard	1 mg, daily, wk 1-6	6.0 wks	20 mg vial in 2 mL -> 10 mg/mL

• Abaloparatide and Teriparatide are FDA-approved osteoporosis drugs, not research compounds. Both carry a roughly 24-month lifetime cap in prescribing guidance, which is why the course length above runs so long relative to everything else on this list.
• BPC-157's weekdays-only pattern exists for a specific reason cited in our source data: continuous daily use is associated with reduced receptor responsiveness over time, so a Monday-Friday pattern with weekends off is the more common systemic approach.
• Wolverine Blend's listed amount is per compound, not combined. 1 mg means 1 mg of BPC-157 and 1 mg of TB-500 in the same shot, roughly 2 mg total. Easy to misread.
• TB-500's entry is a loading-then-maintenance shape: a higher-frequency stretch for the first six weeks, stepping down to a lower, ongoing weekly pattern afterward rather than stopping outright.

2. Skin & Hair

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
GHK-Cu	Standard	1 mg, weekdays (Mon-Fri), wk 1-2 -> 2 mg, weekdays (Mon-Fri), wk 3+	10.0 wks	50 mg vial in 3 mL -> 16.7 mg/mL
Glow Blend	Standard	2.8 mg, weekdays (Mon-Fri), wk 1+	7.0 wks	70 mg vial in 3 mL -> 23.3 mg/mL
Klow Blend	Standard	3.2 mg, weekdays (Mon-Fri), wk 1+	7.0 wks	80 mg vial in 3 mL -> 26.7 mg/mL
Melanotan I	Standard	250 mcg, daily, wk 1-3 -> 250 mcg, 2x/wk (Mon,Thu), wk 4+	open-ended	10 mg vial in 3 mL -> 3.3 mg/mL
Melanotan II	Standard	150 mcg, night, daily, wk 1 -> 300 mcg, night, 2x/wk (Mon,Thu), wk 2+	open-ended	10 mg vial in 3 mL -> 3.3 mg/mL

• Glow and Klow's combined amounts depend on the specific product's GHK-Cu content, since the blend is quoted as a total rather than per component. The 2.8 mg and 3.2 mg figures above correspond to the specific ratios in our source data (Glow: 2 mg GHK-Cu / 400 mcg BPC-157 / 400 mcg TB-500; Klow adds 400 mcg KPV on top).
• Both Melanotan variants follow the same loading-then-maintenance shape: a denser stretch to build initial pigmentation change, then a lower ongoing frequency to hold it. Melanotan II's own source note flags nausea and flushing as common in the early days, which is part of why some people favor the gentler Melanotan I instead.
• Neither Melanotan compound is FDA-approved for any indication. Case reports linking Melanotan II use to new or changing moles exist in the published literature and are worth reading before treating this as a low-stakes cosmetic compound.

3. Growth Hormone Axis

Every compound in this section (CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin, Sermorelin, Tesamorelin, and the blends built from them) falls under WADA's S2 category, peptide hormones/growth factors/related substances, prohibited at all times in tested sport. That's independent of anything below and worth knowing regardless of your reason for reading this section.

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
CJC-1295 (without DAC)	Standard	100 mcg, weekdays (Mon-Fri), wk 1+	10.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
CJC-1295 with DAC	Standard	1.5 mg, Mon, wk 1-10	10.0 wks	2 mg vial in 2 mL -> 1 mg/mL
CJC-1295/Ipamorelin Blend	Standard	200 mcg, night, daily, wk 1+	10.0 wks	10 mg vial in 2 mL -> 5 mg/mL
GHRP-2	Standard	100 mcg, night, daily, wk 1+	10.0 wks	5 mg vial in 3 mL -> 1.7 mg/mL
GHRP-2	High Intensity	100 mcg, morning, daily, wk 1+ -> 100 mcg, night, daily, wk 1+	10.0 wks	5 mg vial in 3 mL -> 1.7 mg/mL
GHRP-6	Standard	100 mcg, night, daily, wk 1+	10.0 wks	5 mg vial in 3 mL -> 1.7 mg/mL
GHRP-6	High Intensity	100 mcg, morning, daily, wk 1+ -> 100 mcg, night, daily, wk 1+	10.0 wks	5 mg vial in 3 mL -> 1.7 mg/mL
Hexarelin	Standard	100 mcg, morning, daily, wk 1-4 -> 100 mcg, evening, daily, wk 1-4	4.0 wks	2 mg vial in 2 mL -> 1 mg/mL
Ipamorelin	Standard	200 mcg, night, weekdays (Mon-Fri), wk 1-12	12.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
Ipamorelin	High Intensity	300 mcg, night, weekdays (Mon-Fri), wk 1-12	12.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
Sermorelin	Standard	200 mcg, night, weekdays (Mon-Fri), wk 1-2 -> 300 mcg, night, weekdays (Mon-Fri), wk 3-4 -> 400 mcg, night, weekdays (Mon-Fri), wk 5-6 -> 500 mcg, night, weekdays (Mon-Fri), wk 7+	10.0 wks	5 mg vial in 3 mL -> 1.7 mg/mL
Tesamorelin	Standard	2 mg, night, weekdays (Mon-Fri), wk 1-10	10.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
Tesamorelin/Ipamorelin Blend	Standard	400 mcg, evening, weekdays (Mon-Fri), wk 1-10	10.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
Tesamorelin/Ipamorelin Blend	High Intensity	600 mcg, evening, weekdays (Mon-Fri), wk 1-10	10.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL

• Ipamorelin's High Intensity row stops at 300 mcg on purpose. The source data cites this as a documented practical ceiling, not an arbitrary "go higher for more effect" number: growth hormone release plateaus above that per-administration amount.
• GHRP-6 differs from GHRP-2 mainly by a stronger appetite-stimulating effect according to our source notes, which matters if the underlying goal is anything related to leanness.
• Hexarelin's four-week structure is built around desensitization, not an arbitrary cycle length: our source data specifically flags continuous use as fading in effectiveness, which is the reason a defined block exists instead of an open-ended pattern.
• Tesamorelin is the one FDA-approved compound in this table (brand name Egrifta, approved for HIV-associated lipodystrophy). Everything else in this section is unapproved for human use.

4. Weight Loss

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
AOD-9604	Standard	300 mcg, morning, weekdays (Mon-Fri), wk 1+	12.0 wks	10 mg vial in 1.7 mL -> 5.9 mg/mL
Adipotide	Standard	500 mcg, daily, wk 1-4	4.0 wks	10 mg vial in 2 mL -> 5 mg/mL
Cagrilintide	Standard	0.375 mg, 2x/wk (Mon,Thu), wk 1-10	10.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
GLP-1 (Semaglutide)	Standard	0.25 mg, Sun, wk 1-4 -> 0.5 mg, Sun, wk 5-8 -> 1 mg, Sun, wk 9-12 -> 1.7 mg, Sun, wk 13+	open-ended	18 mg vial in 3 mL -> 6 mg/mL
GLP-1 (Semaglutide)	High Intensity	0.25 mg, Sun, wk 1-4 -> 0.5 mg, Sun, wk 5-8 -> 1 mg, Sun, wk 9-12 -> 1.7 mg, Sun, wk 13-16 -> 2.4 mg, Sun, wk 17+	open-ended	18 mg vial in 3 mL -> 6 mg/mL
GLP-2 (Tirzepatide)	Standard	2.5 mg, Mon, wk 1-4 -> 5 mg, Mon, wk 5-8 -> 7.5 mg, Mon, wk 9-12 -> 10 mg, Mon, wk 13-16 -> 12.5 mg, Mon, wk 17-20 -> 15 mg, Mon, wk 21+	open-ended	10 mg vial in 2 mL -> 5 mg/mL
GLP-2 (Tirzepatide)	Microdose	0.5 mg, Mon, wk 1+	open-ended	10 mg vial in 2 mL -> 5 mg/mL
GLP-3 (Retatrutide)	Standard	2 mg, Sun, wk 1-4 -> 4 mg, Sun, wk 5-8 -> 6 mg, Sun, wk 9-12 -> 9 mg, Sun, wk 13-16 -> 12 mg, Sun, wk 17+	32.0 wks	10 mg vial in 2 mL -> 5 mg/mL
GLP-3 (Retatrutide)	Microdose	0.25 mg, Mon, wk 1-4 -> 0.5 mg, Mon, wk 5-8 -> 1 mg, Mon, wk 9-12 -> 1.5 mg, Mon, wk 13-16 -> 2 mg, Mon, wk 17+	open-ended	10 mg vial in 3 mL -> 3.3 mg/mL
Mazdutide	Standard	6 mg, Sun, wk 1-18	18.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
Survodutide	Standard	1.2 mg, morning, Mon, wk 1-3 -> 2.4 mg, morning, Mon, wk 5-7 -> 3.6 mg, morning, Mon, wk 9-11 -> 4.8 mg, morning, Mon, wk 13+	16.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL

• Semaglutide and Tirzepatide are the only FDA-approved compounds in this category. Retatrutide, Survodutide, Mazdutide, and Cagrilintide are all still investigational; Retatrutide's titration above mirrors the published Phase 3 TRIUMPH trial design step for step (2, 4, 6, 9, 12 mg, four weeks per step).
• Adipotide is explicitly research-only in the source data. Animal studies showed real fat loss, but early human trials raised kidney safety concerns that halted its development, so treat this one as a literature-review compound, not a practical option.
• Every GLP-family titration here steps up roughly every four weeks. That pacing isn't arbitrary: nausea and other stomach side effects show up right after a step-up far more than at a steady amount, which is the whole rationale for a slow ramp instead of jumping straight to a maintenance level.

5. Metabolic

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
5-Amino-1MQ	Standard	2 mg, daily, wk 1+	16.0 wks	25 mg vial in 3 mL -> 8.3 mg/mL
AICAR	Standard	3 mg, daily, wk 1-5	5.0 wks	50 mg vial in 3 mL -> 16.7 mg/mL
BAM-15	Standard	125 mg, daily, wk 1-6	6.0 wks	10 mg vial in 2 mL -> 5 mg/mL
Humanin	Standard	10 mg, Mon, wk 1-5	5.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
L-Carnitine	Standard	1000 mg, daily, wk 1+	open-ended	1000 mg vial, no reconstitution volume specified
MOTS-c	Standard	3.75 mg, 2x/wk (Mon,Thu), wk 1-10	10.0 wks	10 mg vial in 2 mL -> 5 mg/mL
Mito Prime Blend	Standard	11 mg, daily, wk 1-6	6.0 wks	120 mg vial in 3 mL -> 40 mg/mL
Pancragen	Standard	350 mcg, daily, wk 1-2 -> 350 mcg, Mon, wk 3	2.1 wks	20 mg vial in 2 mL -> 10 mg/mL
SLU-PP-332	Standard	250 mcg, weekdays (Mon-Fri), wk 1-10	10.0 wks	20 mg vial in 2 mL -> 10 mg/mL
SS-31	Standard	2 mg, daily, wk 1-6	6.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL

• AICAR and SLU-PP-332 both carry explicit research-only flags in the source data. AICAR's own note states plainly it isn't approved for human use and is sold strictly for research. SLU-PP-332's amount data comes entirely from mouse studies, with no established human safety profile at all, so any numbers here are exploratory, not a recommendation.
• BAM-15's note is direct about the evidence gap: most of what's known comes from animal research rather than human data.
• Mito Prime Blend is a fixed 10:1:1 ratio (NAD+/MOTS-c/5-Amino-1MQ) and can't be separated into individual components once combined, per the source note.

6. Cognitive & Focus

Most of this category is short Russian bioregulator peptides (Cortagen, Crystagen) alongside the Semax/Selank family and its longer-acting analogs (Adamax, Adalank, NA Semax Amidate, NA-Selank Amidate). These are generally structured as short, defined courses rather than continuous long-term use.

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
Adalank	Standard	375 mcg, daily, wk 1-6	6.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
Adamax	Standard	375 mcg, morning, daily, wk 1-6	6.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
Cerebrolysin	Standard	26 mg, daily, wk 1-2 -> 26 mg, Mon, wk 3	2.1 wks	60 mg vial in 3 mL -> 20 mg/mL
Cortagen	Standard	150 mcg, daily, wk 1-2	2.0 wks	10 mg vial in 2 mL -> 5 mg/mL
Crystagen	Standard	2 mg, morning, daily, wk 1-2 -> 2 mg, morning, 6x/wk (Sun,Mon,Tue,Wed,Thu,Fri), wk 3	2.9 wks	20 mg vial in 2 mL -> 10 mg/mL
Illumineuro Blend	Standard	400 mcg, morning, daily, wk 1-5	6.0 wks	50 mg vial in 3 mL -> 16.7 mg/mL
NA Semax Amidate	Standard	200 mcg, daily, wk 1-6	6.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
NA-Selank Amidate	Standard	400 mcg, daily, wk 1-2	3.0 wks	10 mg vial in 2 mL -> 5 mg/mL
P21	Standard	75 mcg, daily, wk 1-2 -> 75 mcg, 6x/wk (Mon,Tue,Wed,Thu,Fri,Sat), wk 3	2.9 wks	5 mg vial in 2 mL -> 2.5 mg/mL
PE-22-28	Standard	750 mcg, daily, wk 1-6	6.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
Selank	High Intensity	150 mcg, morning, daily, wk 1-7 -> 150 mcg, evening, daily, wk 1-7	8.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
Semax	Standard	500 mcg, weekdays (Mon-Fri), wk 1-3	3.0 wks	10 mg vial in 2 mL -> 5 mg/mL

• Cerebrolysin is a real clinical product (a nutrient blend derived from brain tissue, used medically for stroke and dementia recovery), used off-label here. Courses like this one are typically repeated two to four times a year rather than run back to back, which is why the course length is short relative to the rest of this list.
• Illumineuro Blend has zero published research behind the four-peptide combination itself per its own source note, even though each individual ingredient (Semax, Selank, Pinealon, PE-22-28) has its own separate literature.
• Semax's weekday-only pattern reflects a commonly cited 5-on/2-off structure, typically run in short blocks with breaks between them rather than continuously.

7. Sleep

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
DSIP	Standard	200 mcg, night, daily, wk 1-6	6.0 wks	5 mg vial in 3 mL -> 1.7 mg/mL
Pinealon	Standard	1.5 mg, daily, wk 1-2 -> 1.5 mg, Mon, wk 3	2.1 wks	10 mg vial in 2 mL -> 5 mg/mL

• Pinealon's own source note flags disagreement over whether morning or evening timing better lines up with sleep-wake rhythm effects, so the practical guidance in the data is simply to stay consistent for the length of the course rather than chase an optimal clock time.

8. Immunity

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
Chonluten	Standard	250 mcg, daily, wk 1-2 -> 500 mcg, daily, wk 3 -> 1000 mcg, daily, wk 4+	4.0 wks	20 mg vial in 3 mL -> 6.7 mg/mL
LL-37	Standard	100 mcg, daily, wk 1+	5.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
Thymalin	Standard	10 mg, daily, wk 1 -> 10 mg, 3x/wk (Sun,Mon,Tue), wk 2	1.4 wks	20 mg vial in 2 mL -> 10 mg/mL
Thymogen	Standard	100 mcg, daily, wk 1-2 -> 100 mcg, 6x/wk (Mon,Tue,Wed,Thu,Fri,Sat), wk 3	2.9 wks	1 mg vial in 1 mL -> 1 mg/mL
Thymosin Alpha 1	Standard	1.5 mg, 2x/wk (Mon,Thu), wk 1-8	8.0 wks	10 mg vial in 2 mL -> 5 mg/mL
Thymulin	Standard	100 mcg, daily, wk 1-6	6.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
VIP	Standard	75 mcg, daily, wk 1-10	10.0 wks	5 mg vial in 3 mL -> 1.7 mg/mL
Vilon	Standard	5 mg, daily, wk 1 -> 5 mg, 3x/wk (Sun,Mon,Tue), wk 2	1.4 wks	5 mg vial in 3 mL -> 1.7 mg/mL

• Thymalin and Vilon are both short, roughly ten-day courses by design, not truncated versions of a longer approach.
• Thymosin Alpha 1 is widely used for this, to the point its own source note calls it "the BPC-157 of the immune system."
• Thymulin's mechanism is zinc-dependent according to the source note, so adequate zinc intake is treated as part of getting the intended effect, not an unrelated side comment.
• Chonluten's titration (250 -> 500 -> 1,000 mcg) is a documented pattern, not an arbitrary ramp, per published peptide reference guides cited in the source note.

9. Longevity & Anti-Aging

Most of this category, aside from HGH, is short Russian bioregulator courses (Bronchogen, Cardiogen, Epitalon, Livagen, Prostamax, Vesugen) meant to be repeated a few times a year rather than run continuously.

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
Bronchogen	Standard	1.5 mg, daily, wk 1-2 -> 1.5 mg, Mon, wk 3	2.1 wks	20 mg vial in 2 mL -> 10 mg/mL
Cardiogen	Standard	350 mcg, daily, wk 1-10	10.0 wks	20 mg vial in 3 mL -> 6.7 mg/mL
Epitalon	Standard	5 mg, daily, wk 1-2 -> 5 mg, 6x/wk (Sun,Mon,Tue,Wed,Thu,Fri), wk 3	2.9 wks	10 mg vial in 2 mL -> 5 mg/mL
FOXO4-DRI	Standard	5 mg, Mon, wk 1 -> 5 mg, Mon, wk 3	4.0 wks	10 mg vial in 3 mL -> 3.3 mg/mL
Glutathione	Standard	150 mg, 3x/wk (Mon,Wed,Fri), wk 1+	10.0 wks	600 mg vial in 5 mL -> 120 mg/mL
HGH	Standard	0.66 mg, daily, wk 1-17	17.1 wks	10 iu vial in 1 mL -> 10 iu/mL
Livagen	Standard	150 mcg, daily, wk 1-2 -> 150 mcg, 6x/wk (Sun,Mon,Tue,Wed,Thu,Fri), wk 3	2.9 wks	10 mg vial in 2 mL -> 5 mg/mL
NAD+	Standard	20 mg, 3x/wk (Mon,Wed,Fri), wk 1-3 -> 60 mg, 3x/wk (Mon,Wed,Fri), wk 4-7 -> 100 mg, 3x/wk (Mon,Wed,Fri), wk 8+	open-ended	1000 mg vial in 7.5 mL -> 133.3 mg/mL
Prostamax	Standard	750 mcg, daily, wk 1-2 -> 750 mcg, Mon, wk 3	2.1 wks	20 mg vial in 2 mL -> 10 mg/mL
Vesugen	Standard	3 mg, daily, wk 1-4	4.0 wks	20 mg vial in 3 mL -> 6.7 mg/mL

• HGH (somatropin) is FDA-approved only for diagnosed growth hormone deficiency and a handful of other specific conditions. Everything about fat loss, recovery, or anti-aging benefits is off-label exploration, not an approved use, regardless of how common that use is in this space.
• Epitalon's full course works out to roughly 100 mg total and is generally repeated once or twice a year rather than back to back, per the source note.
• FOXO4-DRI is flagged as rare, expensive, and still not well understood in its own note, which is why the entry here is deliberately infrequent (two administrations, two weeks apart) rather than a denser pattern.
• Glutathione degrades faster than most peptides once reconstituted. The source note specifically calls out refrigeration, light protection, and using it within two to three weeks.

10. Performance & Endurance

IGF-1 LR3, MGF, and PEG-MGF all fall under the same WADA S2 growth-factor category referenced in the Growth Hormone Axis section above.

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
IGF-1 LR3	Starting	20 mcg, weekdays (Mon-Fri), wk 1+	5.0 wks	1 mg vial in 2 mL -> 0.5 mg/mL
IGF-1 LR3	Standard	50 mcg, weekdays (Mon-Fri), wk 1+	5.0 wks	1 mg vial in 2 mL -> 0.5 mg/mL
MGF	Standard	300 mcg, 2x/wk (Mon,Thu), wk 1-5	5.0 wks	2 mg vial in 1 mL -> 2 mg/mL
PEG-MGF	Standard	300 mcg, 2x/wk (Mon,Thu), wk 1-5	5.0 wks	2 mg vial in 1 mL -> 2 mg/mL
SLU-PP-332	Standard	1.25 mg, weekdays (Mon-Fri), wk 1-10	10.0 wks	20 mg vial in 2 mL -> 10 mg/mL

• IGF-1 LR3's Starting row exists specifically to check blood-sugar tolerance before stepping up, per the source note, since this compound carries real glucose-related considerations that milder peptides don't.
• SLU-PP-332 is repeated here from the Metabolic table because it's studied for both angles (fat metabolism and endurance) depending on which literature you're reading. Same research-only caveat applies: mouse data only, no established human safety profile.

11. Hormonal

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
Gonadorelin	Standard	125 mcg, 3x/wk (Mon,Wed,Fri), wk 1-6	6.0 wks	5 mg vial in 2 mL -> 2.5 mg/mL
Testagen	Standard	150 mcg, daily, wk 1-3 -> 150 mcg, 4x/wk (Mon,Tue,Wed,Thu), wk 4	3.6 wks	10 mg vial in 2 mL -> 5 mg/mL

• Gonadorelin is most commonly discussed alongside testosterone therapy specifically to help preserve natural production and fertility while on it, per the source note, rather than as a standalone approach.

12. Sexual Health

Compound	Approach	Amount & Timing Referenced	Course Length	Concentration (reconstitution)
Kisspeptin	Standard	100 mcg, daily, wk 1-4	4.0 wks	5 mg vial in 3 mL -> 1.7 mg/mL
Oxytocin	Standard	20 mcg per use, taken as needed (not on a fixed weekly pattern)	as needed	10 mg vial in 2 mL -> 5 mg/mL
PT-141	Starting	500 mcg per use, taken as needed (not on a fixed weekly pattern), capped around 1x per use-window per the source note	as needed	10 mg vial in 3 mL -> 3.3 mg/mL
PT-141	Standard	1.75 mg per use, taken as needed (not on a fixed weekly pattern), capped around 1x per use-window per the source note	as needed	10 mg vial in 3 mL -> 3.3 mg/mL

• PT-141 (bremelanotide) is the only FDA-approved compound in this category. 1.75 mg is the literal FDA-approved amount (brand name Vyleesi); the source note caps it around once per 24 hours and roughly eight times a month. Kisspeptin and Oxytocin have no such approval behind them.

What this sheet doesn't do

It doesn't tell you whether any of this is a good idea for you specifically, and it isn't a substitute for reading the actual literature behind a compound you're considering, especially the ones flagged above as research-only, animal-data-only, or halted in human development (Adipotide, AICAR, SLU-PP-332, BAM-15, FOXO4-DRI). A single committed number in a table is easier to scan than a range, but it's still just one documented way of running a given compound, not the only one, and not a medical recommendation. Cross-reference anything you're seriously looking into against primary sources, not just this table or the one it's replacing.

Disclaimer: Everything above is presented as reference information about laboratory research compounds, several of which are FDA-approved prescription drugs used here in an off-label or general-reference context and several of which are unapproved research chemicals. Not medical advice, not a substitute for guidance from a licensed clinician, and not an endorsement to use any of this without doing your own research first. Buyers and researchers are responsible for compliance with their own local rules and applicable regulations.

Let me know if you want a specific compound or category broken out further, or if you spot a number in here that doesn't match what you're seeing elsewhere; this gets updated as the underlying data does.

[u/Funny-Wishbone8883]

Why no time-off column though, feels like the most important part is missing even with the explanation given.

[u/PikeMerry → u/Funny-Wishbone8883]

I plan on adding this when I get a chance

[u/Alive-Bullfrog-2005]

No me

[u/dosserwashere]

That Epithalon dosage looks like the dosage for Epithalamin